Humana (NYSE:HUM) Now Covered by Piper Sandler

Research analysts at Piper Sandler began coverage on shares of Humana (NYSE:HUM) in a research report issued to clients and investors on Wednesday, MarketBeat reports. The brokerage set an “overweight” rating and a $392.00 price target on the insurance provider’s stock. Piper Sandler’s target price would suggest a potential upside of 7.99% from the stock’s previous close.

Several other equities research analysts also recently issued reports on the company. Wells Fargo & Company dropped their target price on Humana from $413.00 to $350.00 and set an “overweight” rating on the stock in a research report on Monday, April 8th. UBS Group reduced their target price on Humana from $334.00 to $326.00 and set a “neutral” rating for the company in a report on Thursday, April 25th. Cantor Fitzgerald restated a “neutral” rating and issued a $360.00 price objective on shares of Humana in a research report on Wednesday, June 12th. TD Cowen reduced their price objective on shares of Humana from $427.00 to $396.00 and set a “buy” rating for the company in a research note on Tuesday, April 2nd. Finally, Argus cut shares of Humana from a “buy” rating to a “hold” rating in a research note on Wednesday, March 13th. Fourteen analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, Humana has an average rating of “Hold” and an average price target of $409.55.

Humana Stock Performance

NYSE:HUM opened at $362.98 on Wednesday. The company has a market capitalization of $43.74 billion, a P/E ratio of 22.60, a P/E/G ratio of 2.08 and a beta of 0.53. The business has a fifty day simple moving average of $342.12 and a two-hundred day simple moving average of $353.32. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.67 and a quick ratio of 1.67. Humana has a 1 year low of $298.61 and a 1 year high of $530.54.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, topping the consensus estimate of $6.12 by $1.11. The company had revenue of $29.61 billion during the quarter, compared to analyst estimates of $28.52 billion. Humana had a return on equity of 17.76% and a net margin of 1.82%. The firm’s revenue for the quarter was up 10.7% on a year-over-year basis. During the same quarter last year, the firm posted $9.38 EPS. On average, analysts expect that Humana will post 16.12 earnings per share for the current year.

Institutional Trading of Humana

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Norges Bank purchased a new position in Humana during the fourth quarter valued at $676,800,000. Sanders Capital LLC purchased a new stake in Humana in the fourth quarter worth about $489,300,000. Ontario Teachers Pension Plan Board increased its stake in shares of Humana by 11,647.2% during the first quarter. Ontario Teachers Pension Plan Board now owns 1,059,478 shares of the insurance provider’s stock valued at $367,342,000 after purchasing an additional 1,050,459 shares in the last quarter. Putnam Investments LLC lifted its holdings in shares of Humana by 550.3% during the fourth quarter. Putnam Investments LLC now owns 875,489 shares of the insurance provider’s stock valued at $400,808,000 after purchasing an additional 740,858 shares during the last quarter. Finally, Steadfast Capital Management LP bought a new stake in shares of Humana in the 1st quarter worth approximately $158,813,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.